Galmed Pharmaceuticals (GLMD) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Galmed Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLMD, but not buy additional shares or sell existing shares.
View analyst ratings for Galmed Pharmaceuticals or view top-rated stocks.

3 equities research analysts have issued 12 month price targets for Galmed Pharmaceuticals' shares. Their GLMD stock forecasts range from $5.00 to $5.00. On average, they predict Galmed Pharmaceuticals' share price to reach $5.00 in the next year. This suggests a possible upside of 1,034.6% from the stock's current price.
View analysts' price targets for Galmed Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Galmed Pharmaceuticals' stock was trading at $1.82 at the start of the year. Since then, GLMD shares have decreased by 75.8% and is now trading at $0.4407.
View the best growth stocks for 2022 here.

Galmed Pharmaceuticals saw a decline in short interest during the month of July. As of July 15th, there was short interest totaling 35,800 shares, a decline of 66.4% from the June 30th total of 106,600 shares. Based on an average daily trading volume, of 123,800 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the company's shares are sold short.
View Galmed Pharmaceuticals' Short Interest.

Galmed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our earnings forecast for Galmed Pharmaceuticals.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) posted its earnings results on Tuesday, May, 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.09.

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Galmed Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Western Wealth Management LLC (0.24%).

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GLMD stock can currently be purchased for approximately $0.44.

Galmed Pharmaceuticals (NASDAQ:GLMD) has a market capitalization of $11.06 million. The biopharmaceutical company earns $-32,470,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

Galmed Pharmaceuticals employs 18 workers across the globe.

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The official website for Galmed Pharmaceuticals is www.galmedpharma.com. The biopharmaceutical company can be reached via phone at (723) 693-8448, via email at investor.relations@galmedpharma.com, or via fax at 972-3693-8447.